A-STAR: Follow-Up Visit		
Patient Study ID:	Initials:	

Encounter	
Visit date	(DD-MMM-YYYY)
Visit Number	or Baseline

Height and weight		
Height (≤16 years of age)	.  (cm)	
Weight	.   (kg)	

Demographics		
Have there been any changes to the	□ Yes □ No	
demographics since baseline?	If yes, please complete below:	
	Use the highest education level of the patient, or the parents	
	in case of a minor	
Education status (ISCED 2011)	<ul> <li>ISCED 0: Early childhood education ('less than primary' for educational attainment)</li> <li>ISCED 1: Primary education</li> <li>ISCED 2: Lower secondary education</li> <li>ISCED 3: Upper secondary education</li> <li>ISCED 4: Post-secondary non-tertiary education</li> <li>ISCED 5: Short-cycle tertiary education</li> <li>ISCED 6: Bachelor's or equivalent level</li> <li>ISCED 7: Master's or equivalent level</li> <li>ISCED 8: Doctoral or equivalent level</li> </ul>	
Occupation	<ul> <li>Employed</li> <li>Self-employed</li> <li>Disability pension (unable to work)</li> <li>Retired</li> <li>Student or pupil</li> <li>Engaged on home duties</li> <li>Unemployed</li> <li>Other:</li> </ul>	

A-STAR: Follow-Up Visit		
Patient Study ID:	Initials:	

Current eczema treatment (topical therapy)	
Have there been any changes to the topical therapy since last encounter?	<ul> <li>Yes Do</li> <li>If yes, please record and update details in separate <u>Current</u></li> <li><u>Topical Therapy</u> paper CRF.</li> <li>If change was related to an Adverse Event, please complete information on Adverse Event CRF/eCRF.</li> </ul>

Current eczema treatment (phototherapy)	
Have there been any changes to the current phototherapy since last encounter since last encounter?	<ul> <li>Yes Do</li> <li>If yes, please record and update details in separate <u>Current</u></li> <li><u>Phototherapy</u> paper CRF.</li> <li>If change was related to an Adverse Event, please complete information on Adverse Event CRF/eCRF.</li> </ul>

Current eczema treatment (systemic therapy)	
Have there been any changes to the current systemic therapy since last encounter since last encounter?	<ul> <li>Yes Do</li> <li>If yes, please record and update details in separate <u>New</u></li> <li><u>Systemic Therapy</u> paper CRF.</li> <li>If change was related to an Adverse Event, please complete information on Adverse Event CRF/eCRF.</li> </ul>

A-STAR: Follow-Up Visit	
Patient Study ID:	Initials:

Follow-up management (only complete if main eczema treatment has changed)	
Reason for choosing	<ul> <li>Accessibility of treatment (including licensing)</li> </ul>
specific treatment (systemic or phototherapy):	<ul> <li>Anticipation of pregnancy and other family planning issues for both males and females</li> </ul>
phototherapy).	Comorbidities and/or results of baseline investigations
	Drug safety and side effect profile
	<ul> <li>History of prior systemic therapies (including response)</li> </ul>
	Patient age
	Patient preference
	Therapeutic profile (select all that apply)
	O Speed of onset
	O Magnitude of effect
	O Better long-term control after drug is stopped
	□ Other:
Reason for change of	Not applicable
therapy:	Lack of efficacy
	Adverse event (complete Adverse Event CRF)
	Interaction with other medication
	□ Child's wish
	Patient's request
	□ Other:
Reason for	Not applicable
discontinuation of therapy:	Lack of efficacy
тегару.	Adverse event (complete <u>Adverse Event</u> paper CRF)
	Interaction with other medication
	□ Child's wish
	Patient's request
	□ Other:

A-STAR: Follow-Up Visit	
Patient Study ID:	Initials:

## **Concomitant medication**

Have there been any changes in concomitant medications since the last visit? 
Ves 
No

If yes, record details in separate Concomitant Medication paper CRF.

General eczema questions		
Were any days lost from usual activities	N/A (not applicable at Visit 2 (Week 4))	
(e.g. work, study, holiday etc.) due to eczema <u>in the last 3 months</u> ?	🗆 Yes 🗆 No	
	If yes, how many days in total:	
Was there a change in diagnosis after enrolment?	🗆 Yes 🗆 No	
	If yes, please select:	
	O CTCL	
	O Other:	

Healthcare resource use		
Since your last visit, have you visited A&E?	🗆 Yes 🗆 No	
	If yes, was this related to your eczema or to	
	your eczema medication?	
	🗆 Yes 🗆 No	
	If yes, state how many times:	
Since your last visit, have you been admitted to hospital?	🗆 Yes 🗆 No	
	If yes, was this related to your eczema or to	
	your eczema medication?	
	🗆 Yes 🗆 No	
	If related, please list details:	
	Date of admission:	

A-STAR: Follow-Up Visit	
Patient Study ID:	Initials:

	Date of discharge::
	Type of Ward:
	Date of admission:
	Date of discharge::
	Type of Ward:
	Please consider completing the <b>Adverse</b>
	<b>Event</b> and/or <b>Concomitant Medication</b> log.
Since your last visit, have you seen a	🗆 Yes 🗆 No
specialist at the hospital as an outpatient?	If yes, was this related to your eczema or to
	your eczema medication?
	🗆 Yes 🗆 No
	If yes, state how many visits:
Since your last visit, have you seen a GP or	🗆 Yes 🗆 No
a nurse?	If yes, was this related to your eczema or to
	your eczema medication?
	🗆 Yes 🗆 No
	If yes, state how many visits:
Since your last visit, have you been taking	🗆 Yes 🗆 No
any additional medication for your condition?	If yes, please remember to update <u>Concomitant</u> <u>Medication</u> form.

A-STAR: Follow-Up Visit	
Patient Study ID:	Initials:

Skin examination (performed o	n an <b>annual basis</b> with oversight by a dermatologist)
Clinical phenotype	
For guidance on the recognition of flexural and non-flexural eczema (dermatitis) see online training manual.	
Pay particular attention to black skin. Redness may be difficult to see and is not an essential criterion but there must be surface change (i.e. scaling, vesicles, oozing, crusting and/or lichenification).	
Flexural eczema	🗆 Yes 🗆 No
	If yes, which areas are involved (individual patches have to be ≥1cm)?
	O Ankles
	${ m O}$ Flexures of the arms (antecubital fossae)
	O Flexures of the legs (popliteal fossae)
	O Neck
	O Skin fold(s) around the eyes
Non-flexural eczema	🗆 Yes 🗆 No
	If yes, which areas are involved?
	O Arms (at least one patch ≥2cm diameter BOTH sides)
	O Elbows (patch ≥2cm diameter)
	O Face (at least one non-flexural patch ≥2cm diameter)
	O Hands (patch ≥2cm diameter BOTH sides)
	O Knees (patch ≥2cm diameter)
	O Legs (at least one patch ≥2cm diameter BOTH sides)
Evidence of pompholyx (vesicular eczema) or a history of pompholyx	□ Yes □ No

A-STAR: Follow-Up Visit	
Patient Study ID:	Initials:

Discoid eczema (at least 5 circular patches in total, each patch ≥2cm diameter)	🗆 Yes 🗆 No
Nodular prurigo (≥5 palpable nodules of the skin from long- term scratching (usually on the legs or arms), ≥1cm diameter each)	□ Yes □ No
Follicular eczema (widespread eczematous hair follicle involvement, more commonly seen in darker skin types)	□ Yes □ No
Widespread fine scale predominantly affecting the non- flexural areas of the limbs and body (ichthyosis)	□ Yes □ No
Keratosis pilaris (thickening around the base of hair follicles over upper arms, thighs or cheeks)	□ Yes □ No
Palmar hyperlinearity	🗆 Yes 🗆 No
Erythroderma (≥90% BSA involvement)	🗆 Yes 🗆 No

Skin infections	
Current skin infection	🗆 Yes 🗆 No
Swab taken?	□ Yes □ No
Bacterial infections (1)	🗆 Yes 🗆 No
	If yes, organism:

A-STAR: Follow-Up Visit	
Patient Study ID:	Initials:
	O Methicillin Sensitive Staphylococcus Aureus (MSSA)
	O Methicillin Resistant Staphylococcus Aureus (MRSA)
	O Streptococcus
	O Other organism:
	Body site:
Bacterial infections (2)	🗆 Yes 🗆 No
	If yes, organism:
	O Methicillin Sensitive Staphylococcus Aureus (MSSA)
	O Methicillin Resistant Staphylococcus Aureus (MRSA)
	O Streptococcus
	O Other organism:
	Body site:
Viral infections (1)	🗆 Yes 🗆 No
	If yes, organism:
	O Herpes simplex
	O Varicella zoster
	O Other organism:
	Body site:
Viral infections (2)	🗆 Yes 🗆 No
	If yes, organism:
	O Herpes simplex
	O Varicella zoster

A-STAR: Follow-Up Visit	
Patient Study ID:	Initials:

	O Other organism: Body site:
Fungal infection (1)	Fungal scraping taken:  Yes No Organism: Body site:
Fungal infection (2)	Fungal scraping taken:  Yes No Organism: Body site:

Severity assessments (can be done by any appropriately trained staff)	
EASI	Test performed: 🗆 Yes 🛛 No
(Score 0-72)	Date:
	Total score:    .
vIGA-AD™ scale (5-point)	Test performed: 🗆 Yes 🛛 No
	🗆 0 - Clear
	🗆 1 – Minimal
	□ 2 – Mild
	□ 3 – Moderate
	□ 4 – Severe

<b>Patient reported outcomes</b> (can use questionnaires user guides to enter answers from the questionnaires/paper CRF onto the eCRF)	
POEM	Test performed: 🗆 Yes 🛛 No
Please indicate who has completed the form:	Date:
Patient	

A-STAR: Follow-Up	o Visit
Patient Study ID:	Initials:

Itch severity (NRS)	Test performed: 🗆 Yes 🛛 No
	Date:
Please select:	Test performed: 🗆 Yes 🛛 No
EQ5D-Y (4-16 years old )	Date:
EQ5D-5L (adults)	
Please select:	Test performed: 🗆 Yes 🛛 No
O I <b>DQOL</b> (<4 years)	Date:
O <b>CDLQI</b> (4-15 years)	
O <b>DLQI</b> (≥16 years)	
Asthma control test (≥ 12 years)	Test performed: 🗆 Yes 🗆 No
	Date:

Disease control (not applicable at Visit	2 (Week 4))
How many weeks was your atopic eczema well controlled in the past 3 months?	
How may weeks was your atopic eczema completely controlled in the past 3 months?	

Safety investigations
Were any safety tests performed for this visit?  Ves  No
If yes, record details directly into eCRF, or, on separate Safety Tests paper CRF.

A-STAR: Follow-Up	) Visit
Patient Study ID:	Initials:

Imaging at follow-up	
Have any of these scans been	- Chest X-ray:  Yes No
performed?	If yes, date:
	- CT scan:  Ves INO
	If yes, date:
	- MRI scan: 🗆 Yes 🗆 No
	If yes, date:
	- Fibroscan:  Ves  No
	If yes, date:
	If yes, please tick result:
	Cirrhosis
	Fatty Liver Disease
	Normal
	□ Not performed
	□ Not reported
	O Fibroscan Score :

## Adverse events

Did adverse events occur since the last visit? 
Ves 
No

If yes, record details in separate Adverse Event paper CRF.

A-STAR: Follow-Up	o Visit
Patient Study ID:	Initials:

Research sample donation (ALL SITES)	
Sample for DNA extraction	Has the patient consented?
	Has the research sample been taken? $\Box$ Yes $\Box$ No
	If yes, date of research sample taken:

## **Bioresource samples (BIORESOURCE SITES ONLY)**

Were any Bioresource samples this visit? 
Ves 
No

If yes, record details in separate **<u>Bioresource Samples</u>** paper CRF.

Details of team member completing/overseeing the skin examination (if applicable)	
Name:	
Details of team member completing this CRF	
Name:	
Signature:	
Date:	